Article
PARP1-specific inhibitor displays PARP1-detrapping activity.
Cell reports - 26 May 2026
Schützenhofer Kira, Laker Ellen, Tsang Kyle, Baretić Domagoj, Suskiewicz Marcin J, Zobel Florian F H, Simmons Michael D R, Chatrin Chatrin, Smith Rebecca, Ahel Ivan
Abstract excerpt
The successful use of PARP inhibitors against primarily homologous recombination-deficient tumors relies on their ability to inhibit the catalytic activity of PARP1 and PARP2, leading to their retention at sites of DNA damage, known as PARP "trapping." Different PARP inhibitors vary in their trapping ability and thus in their resulting toxicity. Here, we develop an inducible complementation system for the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.